A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)

The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.

The key Inclusion Criteria include but are not limited to: * Is generally healthy based on medical history and physical examination. The key Exclusion Criteria include but are not limited to: * Has a known or suspected impairment of immunological function. * Has a history of congenital or acquired immunodeficiency. * Has a documented human immunodeficiency virus (HIV) infection or is breastfeeding from a mother with documented HIV infection. * Has a documented history of hepatitis B or C infection. * Has a bleeding disorder contraindicating subcutaneous vaccination or repeated venipuncture. * Has a serious or progressive disease, including but not limited to cancer, uncontrolled diabetes, severe cardiac, renal or hepatic insufficiency, or systemic autoimmune or neurologic disorders. * Has a known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders. * Previous receipt of a dengue vaccine or plans to receive any dengue vaccine (investigational or approved) for the duration of the study (other than the study vaccine). * Received systemic corticosteroids \